Last reviewed · How we verify
Placebo Lachesis
Placebo Lachesis is an inert control substance used in clinical trials to establish baseline efficacy and safety comparisons.
At a glance
| Generic name | Placebo Lachesis |
|---|---|
| Sponsor | Shaare Zedek Medical Center |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it contains no active pharmaceutical ingredient and serves as a comparator arm in randomized controlled trials. It allows researchers to distinguish genuine drug effects from placebo response and natural disease progression. Placebo Lachesis specifically appears to be a homeopathic preparation, though the active mechanism (if any beyond placebo effect) is not established by conventional pharmacology.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Lachesis CI brief — competitive landscape report
- Placebo Lachesis updates RSS · CI watch RSS
- Shaare Zedek Medical Center portfolio CI